Reata Sells Asian Rights to CKD Drug, But Plans To Remain A Solo Act In U.S.
The privately-held Texas biotech gets $35 million upfront from Kyowa Hakko Kirin and sets its sights on a 2011 NDA filing in the U.S.
The privately-held Texas biotech gets $35 million upfront from Kyowa Hakko Kirin and sets its sights on a 2011 NDA filing in the U.S.